Clinical trials: Response Evaluation
AIDS
Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose
The purpose of this study is to evaluate the safety and reactogenicity of one booster dose of a HIV candidate vaccine after administration of one oral dose of chloroquine.
- Trial name
- NCT00972725
- Testing
- GSK Biologicals' HIV vaccine (732461), Chloroquine
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
The purpose of this study is to determine whether Apremilast is safe and effective in the treatment of patients with rheumatoid arthritis, specifically in improving signs and symptoms of rheumatoid arthritis (tender and swollen…
- Trial name
- NCT01285310
- Testing
- Apremilast 30 mg, Apremilast 20 mg
- Where
- 50 sites in United States, Czechia and 2 more
- Volunteers
- 237 people
- Sponsor
- Amgen
Inflammatory Bowel Disease, Ulcerative Colitis
Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator
The immunogenicity of anti-tumor necrosis factor alpha (anti-TNF) therapy in inflammatory bowel disease (IBD) is an important cause of loss of response to therapy that may lead to escalation of dose or discontinuation of therapy.
- Conditions
- Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
- Trial name
- NCT02413047
- Testing
- Azathioprine, 6 mercaptopurine, Methotrexate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Indiana University
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65…
- Trial name
- NCT05559476
- Testing
- RSVPreF3 OA investigational vaccine, FLU HD vaccine
- Where
- 46 sites in United States
- Volunteers
- 1,029 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.
This open-label, single arm study will assess the effect of RoActemra/Actemra (tocilizumab) on neutrophils and monitor safety and benefit-risk of RoActemra/Actemra treatment in patients with active rheumatoid arthritis who have…
- Trial name
- NCT01195272
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B
Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg)
This study is performed to evaluate the persistence of anti-hepatitis B surface antigen (HBs) antibodies up to 16, 17, 18, 19 and 20 years after administration of the first dose of the study vaccine, Engerix-B™.
- Trial name
- NCT00240539
- Testing
- Blood sampling
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib
Primary Objective for this study is to evaluate changes in chronic low grade non-hematological adverse events experienced by patients who have been treated with at least 6 months of imatinib and who have not responded to…
- Trial name
- MACS1532 (NCT02115386)
- Testing
- Nilotinib
- Where
- Russia
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Active Systemic Lupus Erythematosus
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.
- Trial name
- NCT04680637
- Testing
- Efavaleukin Alfa, Standard of Care
- Where
- 150 sites in United States, Austria and 17 more
- Volunteers
- 168 people
- Sponsor
- Amgen
Malignant Solid Neoplasm
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
This phase II trial tests whether combination of talazoparib and temozolomide works to shrink tumors in patients with rare cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of…
- Trial name
- NCT05142241
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Meningitis, Meningococcemia
Immunology and Safety of Menactra® in Children in Saudi Arabia
This study will be conducted among children in Saudi Arabia who previously received two doses of A, C, Y, W-135 polysaccharide vaccine before the age of 2 years, and in meningococcal vaccine-naïve children (Control Group).
- Trial name
- NCT00539032
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Gastroparesis
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis.
- Trial name
- NCT04026997
- Testing
- CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- CinDome Pharma, Inc.
Infections, Rotavirus, Rotavirus Vaccines
A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.
This study will provide data on the immune response and safety of GSK Biologicals' HRV liquid vaccine when given along with the routine infant immunizations in Philippines.
- Trial name
- NCT00432380
- Testing
- Rotarix™
- Where
- Philippines
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis
A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis
The purpose of this study is to assess the safety and tolerability of different doses of PF-06444753 and PF-06444752 in subjects with allergic rhinitis.
- Trial name
- NCT01723254
- Testing
- IGE-1, IGE-2, Saline
- Where
- 4 sites in Canada
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Pfizer
Focal Onset Seizures
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
The purpose of this study is to evaluate the efficacy of up to 3 dose levels of adjunctive JNJ-40411813 compared to placebo based on the time to baseline monthly seizure count in participants with focal onset seizures who are…
- Trial name
- NCT04836559
- Testing
- JNJ-40411813
- Where
- 69 sites in United States, Belgium and 6 more
- Volunteers
- 110 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis RA
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA). Phase 2a.
- Trial name
- NCT03410056
- Testing
- Efavaleukin alfa
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Amgen
Uterine Cervical Neoplasms
FLT PET Imaging for Cervical Cancer
Our primary hypothesis is that [18F]FLT PET can identify active bone marrow in addition to metabolically active tumor. This trial will use FLT-PET imaging to define areas of active bone marrow in the pelvis.
- Trial name
- NCT01075412
- Testing
- [F18]Fluorothymidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Iowa
Hepatitis C Virus (HCV)
Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
A study to evaluate the efficacy and safety of glecaprevir(GLE)/pibrentasvir(PIB) in treatment-naïve participants with chronic hepatitis C virus (HCV) genotypes 1-6 infection and with an aspartate aminotransferase to platelet…
- Trial name
- NCT03212521
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 42 sites in United States, Bulgaria and 8 more
- Volunteers
- 230 people
- Sponsor
- AbbVie
Major Depressive Disorder
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
This study will evaluate the efficacy of ALKS 5461 when administered daily for 4 weeks to adults with Major Depressive Disorder (MDD) and inadequate response to antidepressant therapy.
- Trial name
- NCT01500200
- Testing
- ALKS 5461
- Where
- 27 sites in United States
- Volunteers
- 142 people
- Sponsor
- Alkermes, Inc.
Diabetes Mellitus, Type 1
A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes
This study has 2 parts. Each participant will receive a daily injection of LY2605541 during one treatment period and a daily injection of insulin glargine during one treatment period.
- Trial name
- NCT01769404
- Testing
- LY2605541, Insulin Glargine
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients
This is a pilot study of implement multi-parametric MR imaging for organ delineation and tumor response assessment of prostate cancer patients being treated with radiation therapy.
- Trial name
- NCT03180398
- Testing
- Multiparametric MRI
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System